Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Corneal Endothelium Clear all
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

NCT06041256
View directory record Official record
Conditions
Corneal Edema, Corneal Endothelial Dysfunction
Interventions
AURN001, Corneal Endothelial Cells, Y27632
Combination Product · Biological · Drug
Lead sponsor
Aurion Biotech
Industry
Eligibility
18 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

NCT00763360
View directory record Official record
Conditions
Cataract
Interventions
DisCoVisc®, Healon, Amvisc Plus
Device · Drug
Lead sponsor
Alcon Research
Industry
Eligibility
49 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Jun 27, 2026, 5:12 AM EDT
Terminated No phase listed Observational

Using the Optovue OCT to Select IOL Power

NCT01361282
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Cataract
Interventions
Not listed
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jun 27, 2026, 5:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

NCT02118922
View directory record Official record
Conditions
Keratoconus, Ectasia, Crosslinking, Fuchs' Endothelial Dystrophy
Interventions
Brillouin imaging
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Life 4°C Versus Optisol in Corneal Storage Media

NCT01657500
View directory record Official record
Conditions
Complications of Corneal Transplant
Interventions
Corneal donor storage in Optisol GS media solution, Life 4°C solution for cornea storage
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
30 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Jun 27, 2026, 5:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

DISCOVER Study: Microscope-integrated Intraoperative OCT Study

NCT02423213
View directory record Official record
Conditions
Retinal Diseases, Fuchs Endothelial Dystrophy, Macular Hole, Epiretinal Membrane, Retinal Detachment
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05795699
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 27, 2026, 5:12 AM EDT
Recruiting Phase 4 Interventional

Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

NCT03249337
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Ripasudil hydrochloride hydrate 0.4% ophthalmic solution
Drug
Lead sponsor
Marian Macsai, MD
Other
Eligibility
18 Years to 91 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

NCT05136443
View directory record Official record
Conditions
Corneal Endothelial Dystrophy, Corneal Edema
Interventions
loteprednol etabonate 0.25% ophthalmic suspension
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

NCT04520321
View directory record Official record
Conditions
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Interventions
TTHX1114(NM141), Vehicle (placebo)
Drug · Other
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jun 27, 2026, 5:12 AM EDT
Completed No phase listed Observational

Comparative Study of Specular Microscopes for Endothelial and Corneal Cell Measurements

NCT02138266
View directory record Official record
Conditions
Corneal Endothelial Cell Loss
Interventions
Topcon Specular Microscope SP-1P, Konan Specular Microscope CELLCHEK XL
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

NCT04810962
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jun 27, 2026, 5:12 AM EDT
Terminated Phase 2Phase 3 Interventional

Endothelial Cell Loss After Cataract Surgery

NCT00932191
View directory record Official record
Conditions
Cataracts
Interventions
Standard phacoemulsification, Reduced ultrasound phacoemulsification
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2014 · Synced Jun 27, 2026, 5:12 AM EDT
Enrolling by invitation Not applicable Interventional

Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years

NCT07217249
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation
Interventions
Descemet membrane endothelial keratoplasty
Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
30 Years to 93 Years
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
14
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Not applicable Interventional Results available

Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty

NCT00624221
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy, Corneal Edema
Interventions
Descemet's stripping endothelial keratoplasty
Procedure
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Jun 27, 2026, 5:12 AM EDT
Completed No phase listed Observational Results available

Comparative Study of Specular Microscopes for Measurements of Cell Density, Coefficient of Variation and Hexagonality

NCT02276638
View directory record Official record
Conditions
Corneal Endothelial Cell Loss
Interventions
Specular Microscope Nidek CEM-530, Specular Microscope Konan CELLCHEK XL
Device
Lead sponsor
Nidek Co. LTD.
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jun 27, 2026, 5:12 AM EDT
Recruiting Phase 3 Interventional

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07368959
View directory record Official record
Conditions
Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Interventions
Combination Product: AURN001 + Y-27632, Placebo
Drug · Other
Lead sponsor
Aurion Biotech
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Mesa, Arizona • Little Rock, Arkansas • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 27, 2026, 5:12 AM EDT
Recruiting Phase 4 Interventional

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

NCT04853251
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
Device · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
51
States / cities
Mesa, Arizona • Bakersfield, California • Huntington Beach, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Not applicable Interventional Results available

Cornea Donor Study

NCT00006411
View directory record Official record
Conditions
Corneal Disease, Fuch's Dystrophy, Pseudophakic Corneal Edema
Interventions
corneas assigned by donor age group
Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
40 Years to 80 Years
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Study of Endothelial Keratoplasty Outcomes

NCT00800111
View directory record Official record
Conditions
Fuchs' Endothelial Corneal Dystrophy, Bullous Keratopathy, Iridocorneal Endothelial Syndrome, Posterior Polymorphous Dystrophy
Interventions
endothelial keratoplasty
Procedure
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
2,593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Phase 3 Interventional

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05826353
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Not applicable Interventional

A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema

NCT00346138
View directory record Official record
Conditions
Fuchs Dystrophy, Corneal Edema
Interventions
Corneal transplantation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Jun 27, 2026, 5:12 AM EDT
Not listed Phase 4 Interventional

Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK)

NCT01357122
View directory record Official record
Conditions
Fuchs' Corneal Endothelial Dystrophy
Interventions
NCI Insertion, Standard Forceps Insertion
Device · Procedure
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Jun 27, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)

NCT01448213
View directory record Official record
Conditions
Fuchs' Dystrophy, Bullous Keratopathy
Interventions
Prednisolone acetate, Fluorometholone
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Jun 27, 2026, 5:12 AM EDT